Please assess the completion status of the following clinical trial:

Trial Title: Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women with documented CHD (i.e., a prior MI, coronary revascularization procedure, or \>70% stenosis in at least one coronary artery)~* Age \> 39 years~* Patients also will have an anxiety symptom severity score of at least 8 on the Hospital Anxiety and Depression-Anxiety scale (HADS-A) or a DSM-5 diagnosis of an Anxiety Disorder, such as General Anxiety, Social Anxiety, or Panic Disorder.~The study team plans to actively recruit women and minorities, with at least 50% women and 25% minorities.~Exclusion Criteria:~* An MI or coronary revascularization procedure (i.e., CABG or percutaneous coronary intervention) within the last 3 months~* Unstable angina~* Severe left ventricular dysfunction (ejection fraction \<30%) or decompensated heart failure~* Unrevascularized left main coronary artery stenosis \>50%~* Complete Pacemaker dependence~* Resting BP \>200/120 mm Hg~* Conditions that would preclude randomization to either the drug (e.g., prolonged QT interval, known allergy to or intolerance of escitalopram) or exercise (e.g., musculoskeletal problems or abnormal cardiac response to exercise)~* Patients with a primary psychiatric diagnosis other than Anxiety Disorder will be excluded, including patients with PTSD, OCD, or any of the following DSM-5 diagnoses:~  1. Dementia, delirium;~ 2. Schizophrenia, Schizoaffective, or other psychotic disorder;~ 3. Psychotic features including any delusions or hallucinations; or~ 4. Current alcohol or other substance abuse disorder.~* Similarly, patients who pose an acute suicide or homicide risk or who, during the course of the study, would likely require treatment with additional psychopharmacologic agents will not be enrolled.~* Patients will also be excluded if they are taking other medications that would preclude assignment to either drug or exercise conditions (e.g., clonidine, dicumarol, anticonvulsants, and MAO inhibitors) or are taking herbal supplements with purported mood effects (e.g., St. John's Wort, valerian, ginkgo).~* Patients already engaged in regular exercise (at least 30 minutes \>1x/week) will not be enrolled.~* Finally, pregnant women will be excluded from participation.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supervised Aerobic Exercise (Type: EXPERIMENTAL): Patients will exercise three times per week, under medical supervision, at a level of 70-85% of their VO2peak as determined at the time of their baseline exercise stress test. Patients' exercise will consist of 10 minutes of gradual warm-up exercises followed by 35 minutes of continuous walking, biking, or jogging, and 5 minutes of cool down exercises for a total a 50 minutes per session. Patients will be instructed to monitor their radial pulses and will be checked at least three times per session to ensure that they are within their prescribed exercise training ranges.
- Lexapro (Type: EXPERIMENTAL): Treatment in the medication will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service. The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules. Medication will be dispensed as capsules of escitalopram in individually coded bottles. Medication adherence will be assessed using pill count at each study visit. Patients will visit face-to-face with a study psychiatrist at week 0 (baseline), week 1, week 2, week 4, week 8, and week 12 with phone encounters at weeks 3 and 6. The psychiatrist will make all medication adjustments based primarily upon Spielberger Anxiety Scores. Depending on symptoms, daily escitalopram doses will be titrated to 10 mg after week 2 and to 15 mg or placebo equivalent at week 3 if patients show no change or only minimal improvement.
- Placebo (Type: PLACEBO_COMPARATOR): Treatment in the medication and placebo pill arms will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service, who have extensive experience in clinical trials. Medication will be taken once daily in the morning but can be switched to once daily in the evening if deemed necessary. Placebo medication administration will follow the same protocol as outlined for Lexapro.

Based on this trial design, predict the completion outcome and termination type (if applicable).